166 related articles for article (PubMed ID: 10473076)
1. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
Kudelka AP; Levy T; Verschraegen CF; Edwards CL; Piamsomboon S; Termrungruanglert W; Freedman RS; Kaplan AL; Kieback DG; Meyers CA; Jaeckle KA; Loyer E; Steger M; Mante R; Mavligit G; Killian A; Tang RA; Gutterman JU; Kavanagh JJ
Clin Cancer Res; 1997 Sep; 3(9):1501-5. PubMed ID: 9815836
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP
Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA; Hinton L; Newman RA; Crane EA; Fossella FV; Dordal M; Goodin T; Hong WK
J Clin Oncol; 2002 Nov; 20(22):4440-7. PubMed ID: 12431966
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Figg WD; Pluda JM; Lush RM; Saville MW; Wyvill K; Reed E; Yarchoan R
Pharmacotherapy; 1997; 17(1):91-7. PubMed ID: 9017768
[TBL] [Abstract][Full Text] [Related]
6. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
Dezube BJ; Von Roenn JH; Holden-Wiltse J; Cheung TW; Remick SC; Cooley TP; Moore J; Sommadossi JP; Shriver SL; Suckow CW; Gill PS
J Clin Oncol; 1998 Apr; 16(4):1444-9. PubMed ID: 9552050
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Tran HT; Blumenschein GR; Lu C; Meyers CA; Papadimitrakopoulou V; Fossella FV; Zinner R; Madden T; Smythe LG; Puduvalli VK; Munden R; Truong M; Herbst RS
Cancer Chemother Pharmacol; 2004 Oct; 54(4):308-14. PubMed ID: 15184994
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
15. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Zhu AX; Ready N; Clark JW; Safran H; Amato A; Salem N; Pace S; He X; Zvereva N; Lynch TJ; Ryan DP; Supko JG
Clin Cancer Res; 2009 Jan; 15(1):374-81. PubMed ID: 19118068
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
